Exhibit 107

 

Calculation of Filing Fee Table

 

Form S-4

(Form Type)

 

PIERIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

 

Security
Type

Security
Class Title

Fee
Calculation
or Carry
Forward
Rule

Amount

Registered

Proposed
Maximum
Offering
Price Per
Unit

Maximum
Aggregate
Offering Price

Fee Rate

Amount of
Registration
Fee

Carry
Forward

Form
Type

Carry

Forward

File

Number

Carry
Forward
Initial
effective
date

Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward

Newly Registered Securities

Fees to Be

Paid

Equity

Common

Stock,

$0.001

par value

per share

457(f)

6,919,206 (1)

(2)

$2,306.40 (2)

$0.00014760

$0.34

       
                         

Fees

Previously

Paid

-

-

-

-

-

-

 

-

       

Carry Forward Securities

Carry

Forward

Securities

-

-

-

-

 

-

   

-

-

-

-

 

Total Offering Amounts

 

$2,306.40

-

$0.34

-

-

-

-

 

Total Fees Previously Paid

     

-

       
 

Total Fee Offsets

     

-

       
 

Net Fee Due

     

$0.34

       

 

(1)

Relates to common stock, $0.001 par value per share, of Pieris Pharmaceuticals, Inc., a Nevada corporation, or Pieris, issuable to holders of common stock, $0.0001 par value per share of Palvella Therapeutics, Inc., a Delaware corporation, or Palvella, in the proposed Merger of Polo Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Pieris, with and into Palvella, with Palvella continuing as a wholly owned subsidiary of Pieris and the surviving corporation of the Merger. The amount of Pieris common stock to be registered includes the estimated maximum number of shares of Pieris common stock that are expected to be issued in connection with the Merger, assuming an exchange ratio of approximately 0.315478222 shares of Pieris common stock for each outstanding share of Palvella common stock (which is subject to adjustment prior to closing of the Merger based upon Pieris’ net cash as of the date immediately preceding the closing of the Merger). In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any securities that may be from time to time be offered or issued resulting from forward or reverse stock splits, stock dividends or similar transactions.

 

(2)

Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(f)(2) of the Securities Act of 1933, as amended. Palvella is a private company, no market exists for its securities, and Palvella has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price for the shares expected to be issued pursuant to the Merger is one-third of the aggregate par value of the Palvella securities expected to be exchanged in the Merger.